Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Reasonable pricing" clause

Executive Summary

National Institutes of Health would be directed to reinstate the "reasonable pricing" clause in Cooperative Research & Development Agreements under an amendment sponsored by Rep. Bernie Sanders (I-Vt.) included in the House version of the HHS appropriations bill. The same amendment passed the House last year but was not included in the conference version of the bill, which directed NIH to develop a report on taxpayer-funded research. In the report, NIH repeated its concern that the "reasonable pricing" clause would discourage firms from licensing federal discoveries (1"The Pink Sheet" Aug. 27, p. 3)

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel